Response to “Reply to effectiveness of dutasteride in a large series of patients with FFA in real clinical practice”

Pindado‐­Ortega, Cristina; Saceda‐Corralo, David; Moreno‐Arrones, Óscar M.; Rodrigues-Barata, Ana Rita; Hermosa-Gelbard, Ángela; Jaén‐Olasolo, Pedro; Vañó‐Galván, Sergio

doi:10.1016/j.jaad.2021.03.084

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have previously reported the protective effect of the 5-alpha-reduactase inhibitor, dutasteride, in men with COVID-19, both in hospitalized patients and in an outpatient setting (10)(11)(12). As dutasteride has a half-life of 5 weeks and carries a labeled contraindication for the use in women of childbearing age (18,19), we were keen to explore an antiandrogen that could be applied more broadly. Proxalutamide has been evaluated for 28 days in Phase 1 safety studies for both men and women; furthermore, the half-life is ∼22 h (20).…”

Section: Discussionmentioning

confidence: 99%

“…High flow oxygen devices 1 (1) 26 (19) Invasive mechanical ventilation 0 (0) 17 ( 13) We acknowledge that there are important limitations in the present study. Primarily, no direct monitoring of treatment compliance was conducted; additionally, owing to the open recruitment, complete data for the usual care medications was not available to be analyzed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

McCoy¹,

Goren²,

Cadegiani³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomized, double-blinded, placebo-controlled clinical trial was conducted at two outpatient centers (Brasilia, Brazil). Patients were recruited from October 21 to December 24, 2020 (clinicaltrials.gov number, NCT04446429). Male patients with confirmed COVID-19 but not requiring hospitalization (COVID-19 8-point ordinal scale <3) were administered proxalutamide 200 mg/day or placebo for up to 7 days. The primary endpoint was hospitalization rate at 30 days post-randomization. A total of 268 men were randomized in a 1:1 ratio. 134 patients receiving proxalutamide and 134 receiving placebo were included in the intention-to-treat analysis. The 30-day hospitalization rate was 2.2% in men taking proxalutamide compared to 26% in placebo, P < 0.001. The 30-day hospitalization risk ratio was 0.09; 95% confidence interval (CI) 0.03–0.27. Patients in the proxalutamide arm more frequently reported gastrointestinal adverse events, however, no patient discontinued treatment. In placebo group, 6 patients were lost during follow-up, and 2 patients died from acute respiratory distress syndrome. Here we demonstrate the hospitalization rate in proxalutamide treated men was reduced by 91% compared to usual care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

McCoy¹,

Goren²,

Cadegiani³

et al. 2021

Front. Med.

View full text Add to dashboard Cite

show abstract

“…[11] Moreover, the response was dose-dependent, and the most effective dose was five to seven capsules of dutasteride (0.5 mg) per week. Thus, 5-alpha reductase inhibitors are considered, by most authors, the first therapeutic option in patients with FFA, [22] while others considered them as a second-line therapy [23]. Due to its higher effectivity, dutasteride may be a suitable first option, except for childbearing age women, in which finasteride should be considered because of its shortest wash-out period [22].…”

Section: Systemic Treatmentsmentioning

confidence: 99%

Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris

Porriño‐Bustamante¹,

Fernández‐Pugnaire²

2023

Alopecia Management - An Update

View full text Add to dashboard Cite

The aim of the treatment in frontal fibrosing alopecia and lichen planopilaris is to alleviate symptoms and to arrest the progression of the hair loss, since hair regrowth is not possible once the destruction of hair follicle has happened. Topical corticosteroids and tacrolimus are used to reduce inflammation, but with no clear benefit in slowing the alopecia. Intralesional corticosteroids may obtain hair regrowth in some patients, and they are especially useful in the treatment of eyebrow alopecia in frontal fibrosing alopecia. Regarding systemic treatments, the use of 5-alpha reductase inhibitors has been shown to be the most effective one to get stabilization in frontal fibrosing alopecia and even regrowth in the hairline. Hydroxychloroquine and oral immunomodulators are especially helpful as oral treatment in lichen planopilaris. Low-dose oral isotretinoin is the preferred treatment for facial papules in frontal fibrosing alopecia. The combination of oral and topical treatments is the best therapeutic choice.

show abstract

Response to “Reply to effectiveness of dutasteride in a large series of patients with FFA in real clinical practice”

Cited by 2 publications

References 5 publications

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

RETRACTED: Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

Treatment of Frontal Fibrosing Alopecia and Lichen Planopilaris

Contact Info

Product

Resources

About